Ablynx wins award for 'Most successful early phase trial"
Commenting on the award, Chief Medical Officer Josi Holz said: “It is a great honour to receive this prestigious award. We are pleased that our lead programme, a novel anti-thrombotic, ALX-0081 entered a Phase II study in patients undergoing percutaneous coronary intervention (PCI) last month. The award recognises our innovative Phase I clinical trial design and the acceleration of this programme through the use of biomarkers and PK/PD modelling to establish biological effective dosing in patients. We have achieved the rapid progress with ALX-0081 thanks to a dedicated Ablynx team and our collaborators at the OLVZ in Aalst and PRA International.”
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.